Yahoo Search Búsqueda en la Web

Resultado de búsqueda

1. www.eldebate.com › sociedad › 20240605Un fármaco contra el cáncer de recto logra frenar la ...

   www.eldebate.com › sociedad › 20240605

   • En caché

   Hace 1 día · El último ha tenido que ver con el cáncer de recto. El laboratorio GSK ha actualizado los resultados a largo plazo del estudio colaborativo de fase II de un fármaco que hasta la fecha ha revertido la enfermedad en el 100 % de los pacientes. El ensayo, respaldado por el Memorial Sloan Kettering Cancer Center (MSK), ha evaluado al medicamento ...

2. Videos

   • 

     4:02

     youtube.com

     A Day in the Life | Memorial Sloan Kettering Cancer Center

     20 sept 2016

     77.1K vistas

   • 

     0:31

     youtube.com

     It Takes MSK | Memorial Sloan Kettering Cancer Center

     22 nov 2022

     8.6K vistas

   • 

     7:04

     youtube.com

     Prostate Cancer Detection and Survival Rates | Memorial Sloan Kettering

     11 ago 2010

     20.6K vistas

   Ver todo

3. www.infosalus.com › farmacia › noticia-empresas-gskGSK destaca los buenos resultados de dostarlimab en pacientes ...

   www.infosalus.com › farmacia › noticia-empresas-gsk

   • En caché

   Hace 1 día · MADRID, 5 Jun. (EUROPA PRESS) - La farmacéutica GSK ha actualizado los resultados a largo plazo del estudio colaborativo de fase II, respaldado por el Memorial Sloan Kettering Cancer Center (MSK ...

4. oncodaily.com › blog › 77686Fumiko Ladd Chino: The ASCO24 panel session that gave me the ...

   oncodaily.com › blog › 77686

   • En caché

   Hace 1 día · Fumiko Ladd Chino is a cancer researcher and Assistant Attending in Radiation Oncology at Memorial Sloan Kettering Cancer Center (USA), who specializes in gynecological and breast cancers. She was also a caregiver for her husband Andrew Mark Ladd, PhD who died from cancer in 2007.

5. www.pharmabiz.com › NewsDetailsGSK announces updated, longer-term results from phase II ...

   www.pharmabiz.com › NewsDetails

   • En caché

   Hace 1 día · GSK plc announced updated, longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center (MSK) evaluating Jemperli (dostarlimab) as a first-line treatment—as an alternative to surgery—for mismatch repair deficient (dMMR) locally advanced rectal cancer.

6. www.taipeitimes.com › News › featWeight-loss drugs cut cancer risk by a fifth, research shows

   www.taipeitimes.com › News › feat

   • En caché

   Hace 39 minutos · Researchers from Memorial Sloan Kettering Cancer Center in New York said the jabs could cut the risk of cancer recurrence and be a “new tool” against the disease. A third paper released at ASCO and led by Yale University, also looking at breast cancer patients, suggested taking weight-loss drugs reduced the chances of the disease returning.

7. www.lokmattimes.com › health › new-cancer-drugNew Cancer Drug Claims Unprecedented 100% Cure Rate

   www.lokmattimes.com › health › new-cancer-drug

   • En caché

   Hace 1 día · Scientists have developed a new drug called Jemperli (dostarlimab-gxly), which has successfully eliminated tumors in all 42 patients with locally advanced rectal cancer in a Phase II trial. This drug has shown great potential for treating mismatch repair deficient (dMMR) colorectal cancers, which constitute 5-10% of colorectal cancers.

8. www.newswise.com › articles › mount-sinaiMount Sinai researchers discover potential new the | Newswise

   www.newswise.com › articles › mount-sinai

   • En caché

   Hace 7 horas · MEDIA ADVISORY FOR IMMEDIATE RELEASE: Cell Metabolism, June 4, 2024 Corresponding Author: Isaac Marin-Valencia, MD, PhD, Icahn School of Med